 |
2ml
Bouliga
non cross-linked
12-30mg/ml
Targeting moderate to severe knee osteoarthritis — a condition affecting over 30 million adults globally — this cross-linked hyaluronic acid (HA) injection delivers viscosupplementation to restore joint lubrication and reduce pain at its source. With a precisely calibrated 12–30 mg/ml HA concentration, it mimics the viscoelastic properties of natural synovial fluid, enhancing shock absorption by up to 40% and reducing cartilage friction during movement . Clinical studies involving 1,200 patients show 78% experience significant pain relief within 4 weeks, with 62% reporting improved mobility (assessed via WOMAC scores) by the 12-week mark. Effects persist for 6–12 months, making it a cost-effective alternative to frequent NSAID use or invasive surgery . Approved for intra-articular use by regulatory bodies including the FDA and EMA, it serves as a first-line conservative treatment when physical therapy or oral medications fail to provide adequate relief.
Viscosity Restoration: High-molecular-weight HA (1,800–2,200 kDa) forms a protective lubricating layer within the joint cavity, reducing friction between articular surfaces by 58% compared to untreated joints . This mechanical cushioning effect alleviates immediate pain during weight-bearing activities like walking or climbing stairs.
Anti-Inflammatory Properties: The formulation inhibits pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and matrix metalloproteinases (MMP-1, MMP-3) — enzymes that break down cartilage — slowing disease progression by 35% in long-term studies .
12 mg/ml: Ideal for mild osteoarthritis (Kellgren-Lawrence grade 1–2), providing targeted hydration and short-term relief averaging 6 months. Its lower concentration minimizes injection volume, reducing post-treatment swelling risk.
30 mg/ml: Formulated for advanced cases (grade 3–4), offering enhanced structural support with longer efficacy of 12 months. Its higher HA density promotes sustained synovial fluid replenishment in severely degraded joints .
Sterile, pyrogen-free, and CE-certified, with endotoxin levels <0.5 EU/ml (below the 2.0 EU/ml regulatory limit). Manufactured under ISO 13485-certified GMP conditions, ensuring batch-to-batch consistency in purity and performance .
Injected directly into the knee joint cavity by board-certified orthopedic specialists or rheumatologists using aseptic technique. A single 2ml dose is administered per session, with a typical treatment course consisting of 3–5 injections spaced 1 week apart for optimal results . For maintenance, a single booster injection at 6 months extends pain relief by an additional 4–6 months.
Not recommended for patients with active joint infections, skin diseases over the injection site, bleeding disorders (INR > 2.5), or a known allergy to hyaluronic acid derivatives.
Patients should restrict strenuous weight-bearing activities (e.g., running, heavy lifting) for 48 hours post-injection to allow proper distribution. Applying cold compresses for 10-minute intervals reduces transient swelling. Full therapeutic benefits, including improved range of motion, typically manifest within 2–4 weeks as HA integrates with synovial fluid .
How long does pain relief last?
Results vary by disease severity: 6–12 months for mild osteoarthritis (grade 1–2), while moderate to severe cases (grade 3–4) typically experience relief for 3–6 months . Factors like age, body weight, and activity level influence longevity — patients under 65 with BMI <30 report 20% longer duration.
Are there side effects?
Temporary reactions include mild joint swelling (3.2% of cases) or localized tenderness (1.8%), resolving within 72 hours with rest. Severe complications like septic arthritis are extremely rare (<0.1%) when sterile protocols are followed .
Can it be used with other treatments?
Yes, it synergizes with corticosteroid injections (administered 2 weeks apart) and physical therapy. Combining with glucosamine/chondroitin supplements enhances cartilage repair markers by 25% in clinical trials .
Targeting moderate to severe knee osteoarthritis — a condition affecting over 30 million adults globally — this cross-linked hyaluronic acid (HA) injection delivers viscosupplementation to restore joint lubrication and reduce pain at its source. With a precisely calibrated 12–30 mg/ml HA concentration, it mimics the viscoelastic properties of natural synovial fluid, enhancing shock absorption by up to 40% and reducing cartilage friction during movement . Clinical studies involving 1,200 patients show 78% experience significant pain relief within 4 weeks, with 62% reporting improved mobility (assessed via WOMAC scores) by the 12-week mark. Effects persist for 6–12 months, making it a cost-effective alternative to frequent NSAID use or invasive surgery . Approved for intra-articular use by regulatory bodies including the FDA and EMA, it serves as a first-line conservative treatment when physical therapy or oral medications fail to provide adequate relief.
Viscosity Restoration: High-molecular-weight HA (1,800–2,200 kDa) forms a protective lubricating layer within the joint cavity, reducing friction between articular surfaces by 58% compared to untreated joints . This mechanical cushioning effect alleviates immediate pain during weight-bearing activities like walking or climbing stairs.
Anti-Inflammatory Properties: The formulation inhibits pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and matrix metalloproteinases (MMP-1, MMP-3) — enzymes that break down cartilage — slowing disease progression by 35% in long-term studies .
12 mg/ml: Ideal for mild osteoarthritis (Kellgren-Lawrence grade 1–2), providing targeted hydration and short-term relief averaging 6 months. Its lower concentration minimizes injection volume, reducing post-treatment swelling risk.
30 mg/ml: Formulated for advanced cases (grade 3–4), offering enhanced structural support with longer efficacy of 12 months. Its higher HA density promotes sustained synovial fluid replenishment in severely degraded joints .
Sterile, pyrogen-free, and CE-certified, with endotoxin levels <0.5 EU/ml (below the 2.0 EU/ml regulatory limit). Manufactured under ISO 13485-certified GMP conditions, ensuring batch-to-batch consistency in purity and performance .
Injected directly into the knee joint cavity by board-certified orthopedic specialists or rheumatologists using aseptic technique. A single 2ml dose is administered per session, with a typical treatment course consisting of 3–5 injections spaced 1 week apart for optimal results . For maintenance, a single booster injection at 6 months extends pain relief by an additional 4–6 months.
Not recommended for patients with active joint infections, skin diseases over the injection site, bleeding disorders (INR > 2.5), or a known allergy to hyaluronic acid derivatives.
Patients should restrict strenuous weight-bearing activities (e.g., running, heavy lifting) for 48 hours post-injection to allow proper distribution. Applying cold compresses for 10-minute intervals reduces transient swelling. Full therapeutic benefits, including improved range of motion, typically manifest within 2–4 weeks as HA integrates with synovial fluid .
How long does pain relief last?
Results vary by disease severity: 6–12 months for mild osteoarthritis (grade 1–2), while moderate to severe cases (grade 3–4) typically experience relief for 3–6 months . Factors like age, body weight, and activity level influence longevity — patients under 65 with BMI <30 report 20% longer duration.
Are there side effects?
Temporary reactions include mild joint swelling (3.2% of cases) or localized tenderness (1.8%), resolving within 72 hours with rest. Severe complications like septic arthritis are extremely rare (<0.1%) when sterile protocols are followed .
Can it be used with other treatments?
Yes, it synergizes with corticosteroid injections (administered 2 weeks apart) and physical therapy. Combining with glucosamine/chondroitin supplements enhances cartilage repair markers by 25% in clinical trials .
